Review
doi: 10.1016/S1470-2045(04)01492-5.
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development
Affiliations
- PMID: 15172356
- DOI: 10.1016/S1470-2045(04)01492-5
Item in Clipboard
Review
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development
Lancet Oncol.
2004 Jun.
Abstract
Because of a lack of effective treatments, survival from diffuse pleural mesothelioma remains poor. Many people do not think that treatments for this disease are effective. The understanding of the biology of mesothelioma relevant to the apoptosis-resistant phenotype has been slow to advance. However, this is now changing, and strategies for rational therapeutic drug development are emerging that have the potential to change the natural history and improve survival in the increasing number of patients that will be diagnosed in the next two decades. This review discusses recent developments in apoptosis biology that are specific to mesothelioma and the therapeutic implications for this aggressive cancer.
Comment in
-
Malignant pleural mesothelioma: time for translational research.Lancet Oncol. 2004 Oct;5(10):591; discussion 591-2. doi: 10.1016/S1470-2045(04)01590-6. Lancet Oncol. 2004. PMID: 15465459 No abstract available.
Similar articles
-
Advances in the systemic therapy of malignant pleural mesothelioma.Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. Nat Clin Pract Oncol. 2008. PMID: 18227828 Review.
-
Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.Ann Thorac Cardiovasc Surg. 2008 Jun;14(3):161-5. Ann Thorac Cardiovasc Surg. 2008. PMID: 18577894 Clinical Trial.
-
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.J Clin Oncol. 2005 May 20;23(15):3495-501. doi: 10.1200/JCO.2005.00.802. J Clin Oncol. 2005. PMID: 15908659 Clinical Trial.
-
CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.Clin Cancer Res. 2012 Mar 1;18(5):1447-56. doi: 10.1158/1078-0432.CCR-11-1990. Epub 2012 Jan 18. Clin Cancer Res. 2012. PMID: 22261805
-
Advances in the biology of malignant pleural mesothelioma.Cancer Treat Rev. 2011 Nov;37(7):543-58. doi: 10.1016/j.ctrv.2011.01.001. Epub 2011 Feb 1. Cancer Treat Rev. 2011. PMID: 21288646 Review.
Cited by
-
Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.Mol Cell Biochem. 2011 Nov;357(1-2):83-94. doi: 10.1007/s11010-011-0878-2. Epub 2011 May 19. Mol Cell Biochem. 2011. PMID: 21594647 Free PMC article.
-
Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.PLoS One. 2016 Mar 16;11(3):e0150044. doi: 10.1371/journal.pone.0150044. eCollection 2016. PLoS One. 2016. PMID: 26982031 Free PMC article.
-
Expression of cancer-associated molecules in malignant mesothelioma.Biomark Insights. 2007 May 30;2:173-84. Biomark Insights. 2007. PMID: 19662202 Free PMC article.
-
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.Cell Death Dis. 2011 Jun 23;2(6):e174. doi: 10.1038/cddis.2011.58. Cell Death Dis. 2011. PMID: 21697949 Free PMC article.
-
Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.Thorax. 2014 Jul;69(7):638-47. doi: 10.1136/thoraxjnl-2013-204110. Epub 2014 Feb 24. Thorax. 2014. PMID: 24567297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
